TLDR Biotech
All the top biotech and pharma industry updates, straight to your inbox in only one email. Trusted by 1400+ biotech and pharma professionals.
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | November 18 - 19, 2024
Dr. Oz to lead Medicare & Medicaid, “fail fast” biotech venture foundry Jupiter Bioventures launches with $70M, BeiGene (soon to BeOne Medicines) settles Brukinsa generic spat with MSN Pharmaceuticals, AstraZeneca’s Andexxa FDA adcom chances not looking good after “major safety findings” + 31 more stories
Biotech & Pharma Updates | November 17 - 18, 2024
Intellia's rare heart disorder CRISPR therapy looks solid in Ph1, AstraZeneca exercises option for Quell Therapeutics cell therapy, Novartis & Ratio Therapeutics' $745M radiotherapy development partnership, Neurogene stock drops even further as one Rett syndrome gene therapy recipient now in “critical condition” + 29 more stories
Biotech & Pharma Updates | November 12 - 13, 2024
BioNTech buys bispecific partner Biotheus for $800M, PTC Therapeutics rare disease gene therapy Kebilidi land FDA approval, Adaptimmune touts positive Ph2 lete-cel data, Metsera $215M Series B to fuel obesity ambitions, UK’s NICE agrees to reassess Sanofi’s Sarclisa, Sanofi & Healx partner on finding indications to match a discontinued late stage asset, ICU Medical & Otsuka Pharmaceutical Factory partner on bolstering North American IV solution network, Syros Pharmaceuticals myelodysplastic syndrome drug combo misses Ph3 endpoint, Marinus Pharmaceuticals cuts 45% of staff, a hidden spreadsheet tab cost Amgen $12B in market cap, FDA continues struggling with retaining drug manufacturing site inspectors
Biotech & Pharma Updates | November 11 - 12, 2024
Trace Neuroscience launches with $101M and ALS therapy goals, Apollo Therapeutics buys ex-China rights to Sunshine Lake Pharma diabetes clinical asset, Alentis Therapeutics $181.4M Series D to accelerate ADC pipeline, AstraZeneca plans $3.5B & 1000+ jobs investment in the US, Roche & Flare Therapeutics collaborate on cancer drug discovery, Intercept Pharmaceutical’s full Ocaliva approval rejected by FDA, Neurogene stock collapses after Rett syndrome gene therapy serious adverse event, Bayer’s CEO calls Q3 earnings “not pretty”, Pfizer considers hospital drugs business divestiture as activist investor pressure continues, AstraZeneca’s CEO says they didn’t “lose oversight” regarding Chinese executive criminal investigations
Biotech & Pharma Updates | November 10 - 11, 2024
AbbVie may be feeling buyer's remorse as $8.9B Cereval buy delivers two Ph2 misses, IDEAYA Biosciences exercises licensing option for Biocytogen ADC asset, Novavax flu, COVID-19 vaccines clinical holds lifted, Novelty Nobility $24.8M Series C for solid tumour ADCs, Evotec becomes alleged acquisition target of PE firm Triton Partners, Doctors Without Borders pushes insulin pen makers to offer $1 pens in low and middle-income countries, 23andMe cuts 40% of their staff, Cigna denies considering Humana acquisition, Rapt Therapeutics drops autoimmune small molecule after negative FDA feedback
Biotech & Pharma Updates | November 7 - 10, 2024
Autolous Therapeutic’s leukemia CAR-T nabs FDA approval, AstraZeneca & Amgen tout Tezspire Ph3 data in rhinosinusitis, Travere Therapeutics proposed $125M public offering, AlloVir attempts comeback with Kalaris Therapeutics merger, Daiichi Sankyo and Alteogen partner on subcutaneous Enhertu development, Neurotech’s NT-501 PDUFA date pushed back by 3 months, Allogene reports 3 patient deaths in ALLO-316 Ph1, Eisai cuts full-year Leqembi forecast by $91M, Charles River Labs to close “15 smaller sites”, Genentech drops Nykode Therapeutics cancer vaccine partnership, FDA bans Chinese API manufacturer due to insufficient GMP compliance evidence
Biotech & Pharma Updates | November 6 - 7, 2024
Avid Bioservices goes private for $1.1B, Evotec sells a CDMO site to Monacum Partners, Oblenio Bio launches from Aditum Bio & Leads BioLabs initiative, Gilead posts strong Q3 earnings, JP Morgan looking to raise a later-stage life science fund, Pfizer to invest $1B in China over next 5 years, ADC Therapeutics’ cuts solid tumour hopeful after poor Ph1b showing, Teva Pharmaceuticals stock drops despite Q3 performance, Viracta cuts 42% of staff as part of “resource reprioritization”, Genmab drops development of three cancer-focused antibodies, 72% of biomedical research believe the field is facing a reproducibility crisis
Biotech & Pharma Updates | November 5 - 6, 2024
Incoming Trump admin may be boon to dealmaking but bane to regulatory, Regeneron & Sanofi’s Dupixent lands pediatric approval in Europe, Acadia Pharmaceuticals sells priority review voucher for $150M, Novo Nordisk reports stellar Q3 earnings, Tevogen leverages Microsoft AI partnership to develop allogeneic T-cell therapies, vaccine coalition (including Gavi and WHO) allocate nearly 900k mpox vaccine doses to 9 African countries, Tango Therapeutics glioblastoma hopeful falls flat in Ph1/2 trial, Novo Nordisk decides to abandon chronic kidney disease clinical asset after July Ph3 failure
Biotech & Pharma Updates | November 4 - 5, 2024
Zealand Pharma Ph1 obesity data with less nausea, AstraZeneca plans Ph2b trials for Eccogene licensed obesity hopeful, Vertex beats Q3 analyst expectations, PrognomiQ $34M Series D for early lung cancer detection, Cerebral agrees to $3.7M settlement over unauthorized ADHD/controlled substance prescriptions, Nxera Pharma & Antiverse collab on AI-powered antibody therapeutic design, Merus & Organon both face FDA approval decision delays, Beam Therapeutics first set of sickle cell base editing data includes a patient death (likely due to conditioning regimen), Verrica Pharmaceuticals stock plummets after Q3 results, Sana Biotechnology pivot results in layoffs, AstraZeneca shares take a big hit after speculative reports released on China employee investigations
Biotech & Pharma Updates | November 3 - 4, 2024
Viking’s obesity pill data gets a cold reception, Novo Nordisk’s Wegovy may reduce all-cause hospital admissions according to new Ph3 analysis, BioNTech Q3 earnings beat analyst expectations but 2024 outlook takes a hit, Neurogene PIPEs in $200M, NLS Pharmaceutics & Kadimastem agree on merger, Novo Nordisk partners with Ascendis Pharma on GLP-1 delivery tech, FDA makes Rare Disease Innovation Hub progress, Sun Pharma’s Leqselvi launch delayed by Incyte-instigated injunction over alleged patent infringement, Mark Cuban’s Cost Plug Drugs hit with FDA Form 483